[18f]f-resca-g5
Appendix Cancer
RenJi HospitalradiopharmaceuticalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Appendix Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | BB |
MITOMYCIN C National Cancer Institute (NCI) | Phase 2 | B |
Sodium Thiosulfate National Cancer Institute (NCI) | Phase 2 | B |
Nilotinib National Cancer Institute (NCI) | Phase 2 | B |
Floxuridine Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
View all 26 →
Same molecule, other indications
[18f]f-resca-g5 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →